Entrada Therapeutics, Inc. (TRDA) — SEC Filings
Entrada Therapeutics, Inc. (TRDA) — 28 SEC filings. Latest: 10-Q (May 7, 2026). Includes 11 8-K, 7 10-Q, 3 SC 13G/A.
View Entrada Therapeutics, Inc. on SEC EDGAR
Overview
Entrada Therapeutics, Inc. (TRDA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-Q filed on Nov 6, 2025: Entrada Therapeutics, Inc. (TRDA) reported a net loss of $40.5 million for the three months ended September 30, 2025, compared to a net loss of $38.9 million for the same period in 2024, representing a 4.1% increase in loss. For the nine months ended September 30, 2025, the net loss was $120.3 milli
Sentiment Summary
Across 28 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 25 neutral. The dominant filing sentiment for Entrada Therapeutics, Inc. is neutral.
Filing Type Overview
Entrada Therapeutics, Inc. (TRDA) has filed 7 10-Q, 11 8-K, 2 DEFA14A, 2 DEF 14A, 2 10-K, 3 SC 13G/A, 1 SC 13D/A with the SEC between Jan 2024 to May 2026.
Filings by Year
Recent SEC Filings (28)
Risk Profile
Risk Assessment: Of TRDA's 19 recent filings, 2 were flagged as high-risk, 7 as medium-risk, and 10 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $1,614,000 |
| Net Income | $-44,134,000 |
| EPS | $-1.06 |
| Debt-to-Equity | 0.21 |
| Cash Position | $93,286,000 |
| Operating Margin | -2915.1% |
| Total Assets | $412,898,000 |
| Total Debt | N/A |
Key Executives
- ENTR-601-44
- Dr. Robert J. Mulcahy
- Ms. Sarah E. Kelly
- Felix J. Baker
- Julian C. Baker
Industry Context
The biotechnology sector is characterized by high R&D costs, long development cycles, and significant regulatory hurdles. Companies like Entrada Therapeutics rely heavily on innovation and strategic partnerships to advance their pipelines. The current environment demands strong financial management to sustain operations through the lengthy drug development process.
Top Tags
regulatory-filing (4) · 10-Q (4) · Biotechnology (3) · corporate-governance (3) · SEC Filing (3) · 8-K (3) · Clinical Trials (2) · Cash Burn (2) · Net Loss (2) · Pharmaceuticals (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Net Loss (Q3 2025) | $40.5M | Increased from $38.9M in Q3 2024, indicating widening losses. |
| Collaboration Revenue (Q3 2025) | $0.4M | A 97% decrease from $13.2M in Q3 2024, signaling a significant revenue challenge. |
| R&D Expenses (Q3 2025) | $36.9M | Increased from $34.7M in Q3 2024, reflecting continued investment in pipeline. |
| Cash & Marketable Securities (Sep 30, 2025) | $326.8M | Decreased from $419.9M at Dec 31, 2024, showing a substantial cash burn. |
| Shares Outstanding (Oct 31, 2025) | 38,219,232 | Increased from 37,574,538 shares at Dec 31, 2024, indicating potential dilution. |
| Revenue | $0 | No revenue reported for Q2 2025 or H1 2025, consistent with prior year. |
| Net Loss (Q2 2025) | $45.2M | Increased from $38.5M in Q2 2024, indicating widening losses. |
| Net Loss (H1 2025) | $89.7M | Increased from $75.1M in H1 2024, showing a significant rise in losses year-over-year. |
| R&D Expenses (Q2 2025) | $38.1M | Up from $32.5M in Q2 2024, reflecting increased investment in pipeline development. |
| Cash and Cash Equivalents | $250.3M | Decreased from $310.5M at Dec 31, 2024, highlighting a substantial cash burn. |
| Cash Burn (H1 2025) | $60.2M | Represents the decrease in cash and equivalents from Dec 31, 2024, to June 30, 2025. |
| Reporting Period End Date | 20250331 | Indicates the end of the fiscal quarter for which financial data is reported. |
| Filing Date | 20250508 | The date the 10-Q report was officially submitted to the SEC. |
| SEC File Number | 001-40969 | Identifies the company's filing with the SEC |
| IRS Number | 813983399 | Company's Employer Identification Number |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Entrada Therapeutics, Inc. (TRDA)?
Entrada Therapeutics, Inc. has 28 recent SEC filings from Jan 2024 to May 2026, including 11 8-K, 7 10-Q, 3 SC 13G/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of TRDA filings?
Across 28 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 25 neutral. The dominant sentiment is neutral.
Where can I find Entrada Therapeutics, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Entrada Therapeutics, Inc. (TRDA) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Entrada Therapeutics, Inc.?
Key financial highlights from Entrada Therapeutics, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for TRDA?
The investment thesis for TRDA includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Entrada Therapeutics, Inc.?
Key executives identified across Entrada Therapeutics, Inc.'s filings include ENTR-601-44, Dr. Robert J. Mulcahy, Ms. Sarah E. Kelly, Felix J. Baker, Julian C. Baker.
What are the main risk factors for Entrada Therapeutics, Inc. stock?
Of TRDA's 19 assessed filings, 2 were flagged high-risk, 7 medium-risk, and 10 low-risk.
What are recent predictions and forward guidance from Entrada Therapeutics, Inc.?
Forward guidance and predictions for Entrada Therapeutics, Inc. are extracted from SEC filings as they are enriched.